Neonatal Pulmonary Hemorrhage: Clinical Evaluation and Acute Management for Paramedics and Critical Care Teams

Habib Farah Awwad Alanazi[1], Abdullah Rashed Tami Alzuabi[2], Amin Saleha Ali Alshehri[3], Ghareeb Mohammed Ghareeb Alruwaili[4], Mohammed Abulhedie Alamri[5], Faleh Mohammed Lafi Alshalawi[6], Ali Naif Ali Alotaibi[7], Muteb Awnallah Muteb Alotaibi[8], Ali Abdullah Alshehri[9], Hamad Abdulaziz Hamad Alharbi[10]

[1]Medical Detachment, 3rd Special Security Brigade, Dammam, Saudi Arabia
[2]Field Medicine Department, Eastern Sector, Al Ahsa, Saudi Arabia
[3]Ministry of National Guard, Dammam, Saudi Arabia
[4]Military Field Medicine Unit, Eastern Sector, Al Ahsa, Saudi Arabia
[5]Field Medicine Department, Eastern Sector, Dammam, Saudi Arabia
[6]Imam Abdulrahman Al Faisal Hospital, Dammam, Saudi Arabia
[7]King Khalid Military College Health Center, Riyadh, Saudi Arabia
[8]Ministry of National Guard, Dammam, Saudi Arabia
[9]Battalion and Brigade Clinic, Dammam, Saudi Arabia
[10]Medical Ambulance Department, Prince Mohammed bin Abdulrahman Special Security Brigade, Dhahran, Saudi Arabia

Abstract

Background: Neonatal pulmonary hemorrhage is a rare but life-threatening respiratory emergency that predominantly affects preterm and very low birth weight infants. The condition is characterized by bleeding into the pulmonary alveoli and interstitial tissues, leading to acute respiratory failure, hemodynamic instability, and high mortality rates. Early recognition and prompt intervention are essential to improve survival and reduce long-term complications.

Aim: This review aims to examine the etiology, risk factors, clinical presentation, diagnostic evaluation, management strategies, prognosis, and multidisciplinary approaches associated with neonatal pulmonary hemorrhage.

Methods: A narrative review was conducted using current evidence from published studies, systematic reviews, clinical trials, and consensus guidelines addressing neonatal pulmonary hemorrhage. The review synthesizes data regarding epidemiology, pathophysiology, diagnosis, treatment modalities, preventive strategies, and clinical outcomes.

Results: Prematurity, very low birth weight, respiratory distress syndrome, surfactant administration, and hemodynamically significant patent ductus arteriosus were identified as major risk factors. Clinical manifestations commonly include sudden respiratory deterioration, blood-stained airway secretions, hypoxemia, and cardiovascular instability. Diagnostic evaluation relies on clinical findings, chest radiography, laboratory investigations, and echocardiography. Management focuses on rapid stabilization, ventilatory support, correction of coagulopathy, surfactant replacement therapy, and cardiovascular optimization. Despite advances in neonatal intensive care, mortality remains high, ranging from 50% to 68%, and survivors remain at risk for bronchopulmonary dysplasia and neurodevelopmental impairment.

Conclusion: Neonatal pulmonary hemorrhage remains a critical neonatal emergency requiring early diagnosis, immediate respiratory and hemodynamic support, and coordinated multidisciplinary management. Improved preventive strategies and standardized treatment protocols are essential for reducing mortality and improving long-term outcomes in high-risk neonates.

Keywords: Neonatal pulmonary hemorrhage, prematurity, respiratory distress syndrome, patent ductus arteriosus, surfactant therapy, neonatal intensive care, respiratory failure, neonatal emergency.

Introduction

Pulmonary hemorrhage in the neonatal period represents an uncommon yet profoundly severe clinical emergency associated with abrupt physiological deterioration. [1] The condition involves extensive extravasation of blood from the pulmonary capillary network into both the alveolar spaces and the interstitial pulmonary tissue, resulting in the presence of blood-tinged secretions within the airway, including the endotracheal tube when present, and is frequently accompanied by rapid onset respiratory failure and systemic instability. [1][2][3][4] The clinical significance of this condition extends beyond its immediate respiratory impact, as it is strongly associated with elevated neonatal mortality rates, increased dependence on mechanical ventilation, and prolonged duration of intensive care unit hospitalization. [5] From a pathological perspective, pulmonary hemorrhage is often not definitively recognized during the acute clinical course and may instead be identified postmortem. In autopsy evaluations, characteristic findings include

multifocal interstitial and intra-alveolar hemorrhagic infiltration, along with the presence of siderophages within alveolar spaces, indicating prior bleeding episodes within the pulmonary system. [2] Due to its abrupt presentation and overlapping clinical features with other causes of sudden deterioration, it is frequently misclassified, including mistaken attribution to sudden infant death syndrome, which further complicates epidemiological understanding and timely recognition. [2] The rapid progression of pulmonary hemorrhage underscores the critical importance of early identification, risk stratification, and immediate therapeutic intervention, particularly among extremely preterm neonates who remain the most vulnerable population. [2][3][6] The potential for rapid respiratory collapse necessitates heightened clinical vigilance and a proactive diagnostic approach aimed at detecting early warning signs before irreversible decompensation occurs. Although universally accepted clinical guidelines remain limited, effective management relies on comprehensive knowledge of associated risk factors, systematic clinical evaluation, and timely implementation of supportive and corrective interventions. Strengthening clinician awareness and improving structured clinical response strategies are essential measures to improve survival outcomes and reduce long-term morbidity in affected neonates.

Etiology

Neonatal Pulmonary Hemorrhage Risk Factors

Neonatal pulmonary hemorrhage is a multifactorial condition that arises from a complex interaction of prematurity-related vulnerability, hemodynamic instability, inflammatory injury, and iatrogenic influences. The strongest and most consistently reported risk factors include extreme prematurity, particularly gestational age below 32 weeks, and very low birth weight under 1500 g, which reflect the immaturity of pulmonary vascular and alveolar structures and their limited ability to tolerate physiological stress. [4] These baseline vulnerabilities are frequently compounded by additional perinatal and neonatal conditions that further destabilize respiratory and circulatory homeostasis. A broad range of antenatal, intrapartum, and postnatal factors contribute to disease development. These include intrauterine growth restriction, patent ductus arteriosus with significant left-to-right shunting, intrapartum asphyxia, systemic sepsis with increased capillary permeability, circulatory shock, chorioamnionitis, and a spectrum of hematological disorders such as coagulopathy, disseminated intravascular coagulation, thrombocytopenia, anemia, and polycythemia. Blood transfusion has also been identified as a significant precipitating factor, particularly when associated with rapid volume expansion. In such cases, transfusion-related pulmonary hemorrhage may occur secondary to circulatory overload, leading to left ventricular dysfunction, elevated pulmonary venous pressure, and subsequent capillary rupture within the fragile neonatal lung. [3] Additional clinical conditions further increase susceptibility to pulmonary hemorrhage, including respiratory distress syndrome, apnea of prematurity, pulmonary hypoplasia, low Apgar scores, mechanical ventilation, congenital cardiac anomalies, erythroblastosis fetalis, hemorrhagic disease of the newborn, surfactant administration, neonatal encephalopathy, intraventricular hemorrhage, inborn metabolic disorders, and hypothermia. [1][3][6][7][8] Among these diverse factors, the most consistently identified independent predictors include lower gestational age, reduced birth weight, administration of exogenous surfactant, and hemodynamically significant patent ductus arteriosus. [4][6] These variables reflect both structural immaturity and physiological stress responses that predispose the pulmonary circulation to hemorrhagic disruption. The risk of pulmonary hemorrhage increases markedly in neonates born before 32 weeks of gestation, demonstrating a clear inverse relationship between gestational age and disease incidence. [9] This association supports the understanding that underdeveloped pulmonary vasculature, reduced capillary integrity, and immature alveolar architecture create a highly vulnerable respiratory system. In such neonates, exposure to mechanical ventilation further exacerbates injury risk due to high inspiratory pressures, impaired surfactant function, and sudden alveolar overdistension, all of which can precipitate mechanical disruption of the alveolar-capillary barrier. [6] Apnea of prematurity represents an additional mechanistic contributor, particularly when associated with upper airway obstruction or laryngospasm. The resulting episodes of forceful inspiratory effort generate markedly negative intrathoracic pressure, which increases transcapillary stress and promotes structural failure of the delicate alveolar-capillary interface, ultimately leading to pulmonary bleeding. [3] Collectively, these interconnected mechanisms illustrate that neonatal pulmonary hemorrhage is not the result of a single pathological trigger but rather the consequence of multiple converging physiological insults acting on an immature and highly susceptible pulmonary system.

Factors Associated With Pulmonary Hemorrhage in Newborns

The development of neonatal pulmonary hemorrhage is strongly influenced by a complex interplay of respiratory physiology, cardiovascular transition after birth, and therapeutic interventions applied in neonatal intensive care. One important contributing mechanism involves surfactant dysfunction, where the presence of surfactant inhibitors within pulmonary secretions has been associated with impaired alveolar stability and increased susceptibility to alveolar-capillary leakage. [10][11] In this context, endogenous surfactant impairment compromises surface tension regulation, predisposing the immature lung to collapse and mechanical stress injury. However, the administration of exogenous surfactant in preterm infants, particularly those requiring mechanical ventilation, has also been linked to the occurrence of pulmonary hemorrhage. [10][11] This paradox reflects the dual role of surfactant therapy, which while essential for improving lung compliance, may also influence coagulation pathways and alter microvascular integrity. Concerns regarding this potential adverse effect have led to clinical caution in its use despite established recommendations

supporting its administration in preterm neonates by the American Academy of Pediatrics. [4][11] Another major factor implicated in the pathogenesis of pulmonary hemorrhage is hemodynamically significant patent ductus arteriosus. In the transitional circulation of the newborn, a reduction in pulmonary vascular resistance after birth facilitates increased left-to-right shunting through the ductus arteriosus. In cases of hsPDA, this shunting becomes excessive, resulting in marked pulmonary overcirculation, elevated pulmonary capillary hydrostatic pressure, and the development of hemorrhagic pulmonary edema. [7][9] The situation may be further exacerbated following surfactant therapy, which can cause a rapid decline in pulmonary vascular resistance and intrapulmonary pressure. This physiological shift enhances ductal shunting, intensifies pulmonary blood flow, and increases vascular stress, thereby predisposing fragile pulmonary capillaries to rupture and hemorrhage. [6][10][12]



Fig. 1: Pulmonary Hemorrhage in Newborns.

Perinatal asphyxia represents another critical pathological contributor. It can induce left ventricular dysfunction and failure, leading to elevated pulmonary venous pressure and subsequent transudation or leakage of blood into the alveolar spaces. [4] In addition to hemodynamic failure, asphyxia is associated with mechanical stress failure of pulmonary capillaries, particularly in the setting of alveolar overdistention, which further weakens the alveolar-capillary membrane. The combined effects of increased pulmonary blood flow and myocardial dysfunction significantly elevate the risk of hemorrhagic complications in the neonatal lung. [4][7][8] In situations where no identifiable cause or associated risk factor can be determined, the condition is classified as acute idiopathic pulmonary hemorrhage, reflecting the current limitations in fully elucidating its pathophysiological origins. [2] Cardiac shunt physiology also plays a protective or aggravating role depending on the anatomical characteristics of the interatrial communication. An unrestricted foramen ovale has been shown to exert a protective effect against pulmonary hemorrhage by facilitating decompression of the left atrium in the presence of hsPDA. This mechanism allows redistribution of excessive left atrial volume into the right atrium, thereby reducing left-sided pressure overload and preventing pulmonary venous congestion. [5] In contrast, a restrictive foramen ovale or small patent foramen ovale limits this compensatory mechanism, resulting in progressive left atrial distension, increased pulmonary venous pressure, and heightened risk of capillary rupture. In neonates with hsPDA and a restrictive interatrial communication, the postnatal decline in pulmonary vascular resistance leads to unregulated left-to-right shunting, which overwhelms the left atrium and ventricle. This sequence produces significant hemodynamic stress, pulmonary venous congestion, and eventual disruption of the delicate pulmonary microvasculature, culminating in pulmonary hemorrhage. [5] Collectively, these mechanisms highlight that pulmonary hemorrhage is not solely a consequence of isolated pathology but rather the result of dynamic interactions between therapeutic interventions, transitional circulation physiology, and structural cardiac factors in the vulnerable neonatal period.

Epidemiology

Neonatal pulmonary hemorrhage demonstrates a variable incidence across different healthcare settings, reflecting disparities in perinatal care, neonatal intensive care capacity, and underlying population risk profiles. In high-income countries, the reported incidence ranges between 1 and 12 cases per 1000 live births, whereas substantially higher rates are observed in low- and middle-income countries, where limited access to advanced neonatal care and delayed intervention contribute to increased vulnerability. [3][9] These regional differences are also reflected in mortality patterns, with neonatal deaths attributable to pulmonary hemorrhage occurring more frequently in resource-limited settings compared with high-income regions, highlighting the influence of healthcare infrastructure on survival outcomes. [3] The condition is markedly more common among high-risk neonatal populations, particularly premature infants and critically ill newborns requiring intensive care support. In these vulnerable groups, the incidence may rise significantly, reaching approximately 50 per 1000 live births. [4] This elevated rate underscores the strong association between pulmonary hemorrhage and physiological immaturity, especially in neonates with underdeveloped pulmonary vasculature, compromised respiratory mechanics, and unstable cardiovascular adaptation after birth. A slight predominance in female neonates has also been reported in some studies, although the underlying biological or clinical explanation for this gender difference remains unclear. [4] Pulmonary hemorrhage typically presents within the early neonatal period, most frequently occurring within the first 72 hours of life. [1][4][9] This timing corresponds to the critical transitional phase from fetal to neonatal circulation, during which rapid changes in pulmonary vascular resistance and ductal shunting occur. The condition is particularly prevalent among mechanically ventilated newborns, as well as those born with very low birth weight below 1500 g and extreme prematurity. These factors collectively contribute to increased pulmonary fragility and susceptibility to vascular injury. The clinical course is often acute and rapidly progressive, with most cases deteriorating significantly within the first week of life. [6]

A consistent clinical association has been identified between pulmonary hemorrhage and the presence of patent ductus arteriosus with hemodynamically significant left-to-right shunting. [1][9] This hemodynamic abnormality contributes to increased pulmonary blood flow and elevated capillary pressure, which in turn predisposes the fragile neonatal lung to hemorrhagic events. The coexistence of PDA and prematurity further amplifies the risk, creating a pathophysiological environment characterized by pulmonary overcirculation and vascular instability. Within neonatal intensive care units, pulmonary hemorrhage remains a critical and ongoing clinical challenge due to its sudden onset, rapid progression, and high mortality risk. Its epidemiological pattern highlights the importance of early recognition, particularly in the first days of life, and emphasizes the need for vigilant monitoring of high-risk neonates. The burden of disease continues to drive efforts toward improving preventive strategies, optimizing ventilatory and cardiovascular management, and enhancing early diagnostic capabilities to improve overall neonatal outcomes.

History and Physical

Pulmonary hemorrhage in the neonatal period should be considered when blood is detected during tracheal suctioning, particularly in association with sudden and unexplained clinical deterioration. This deterioration is typically characterized by rapidly evolving respiratory compromise, including tachypnea, dyspnea, and tachycardia, alongside progressive oxygen desaturation and escalating ventilatory requirements. [2][3] Hemodynamic instability may also be present, reflecting systemic involvement secondary to impaired gas exchange and acute pulmonary injury. Although the classic presentation is acute and dramatic, clinicians must remain aware that pulmonary hemorrhage can occasionally develop in a more gradual and less obvious manner, which may delay recognition and intervention. [3] The most frequently observed clinical scenario involves a premature neonate, often with underlying respiratory distress syndrome, who develops a sudden onset of frothy, blood-tinged secretions or frank hemorrhage from the respiratory tract. These manifestations may be evident as hemoptysis or epistaxis, and in ventilated infants, bleeding is commonly observed within the endotracheal tube. [1][2] This finding is often accompanied by a rapid decline in respiratory status, necessitating an immediate increase in ventilatory support to maintain adequate oxygenation and ventilation. The presence of such findings in a high-risk neonate should prompt urgent consideration of pulmonary hemorrhage as a primary diagnosis. As the condition progresses, systemic signs of deterioration may become evident. These include hypotonia, bradycardia, recurrent apnea, pallor, and cyanosis, all of which reflect worsening oxygen delivery and impaired cardiopulmonary function. In severe cases, hypovolemic shock may develop due to significant intrapulmonary blood loss and associated circulatory collapse. [1][4] These advanced manifestations indicate a critical stage of disease progression and are associated with a high risk of mortality if not promptly managed. Early recognition of these clinical features is essential for improving outcomes, as timely diagnosis allows for rapid escalation of respiratory and hemodynamic support. In neonatal intensive care settings, a high index of suspicion is required, particularly in preterm infants or those with known risk factors. The combination of respiratory deterioration, blood-stained airway secretions, and ventilatory instability should be regarded as a medical emergency requiring immediate intervention to prevent further progression and potential fatality.

Evaluation

The evaluation of neonatal pulmonary hemorrhage requires a combination of radiological assessment, laboratory investigation, and targeted cardiac imaging to determine severity, identify underlying etiologies, and guide urgent management decisions. Chest radiography remains an initial and essential diagnostic tool, although its findings are not specific for pulmonary hemorrhage. The most common radiographic appearance includes bilateral diffuse

pulmonary infiltrates with a ground-glass pattern, which may closely resemble infectious pneumonia. [2][4] In other cases, imaging may demonstrate patchy or fluffy opacities with focal ground-glass distribution, reflecting uneven alveolar filling with blood. In severe presentations, particularly those involving massive hemorrhage, the lungs may appear completely opacified, producing a "white-out" appearance that indicates near-total alveolar inundation and severe impairment of gas exchange. [2][4] These radiological patterns, while suggestive, must always be interpreted in conjunction with clinical findings due to their overlap with other neonatal respiratory conditions. Laboratory evaluation plays a critical role in assessing the systemic impact of pulmonary hemorrhage and identifying contributing factors. Common findings include anemia resulting from acute blood loss and abnormalities in coagulation parameters, which may indicate an underlying bleeding diathesis or disseminated intravascular coagulation. [2] A comprehensive diagnostic panel is typically required, including complete blood count, blood gas analysis, coagulation profile, crossmatching for potential transfusion, comprehensive metabolic profile, and microbiological studies such as blood cultures. Inflammatory markers including C-reactive protein and procalcitonin are also frequently assessed to evaluate for concurrent infection or sepsis, which may act as precipitating or complicating factors. In addition, cranial ultrasound is recommended to evaluate for intraventricular hemorrhage, a condition that may coexist in preterm neonates and reflects systemic vulnerability to bleeding. Cardiovascular assessment using echocardiography is essential in the evaluation of pulmonary hemorrhage, particularly to identify hemodynamically significant patent ductus arteriosus and associated intracardiac shunting. Serial echocardiographic examinations, including subcostal views, are performed to assess the magnitude and direction of ductal flow, as well as interatrial communication through the foramen ovale. [5] These assessments are crucial for understanding pulmonary overcirculation and left atrial volume overload, both of which contribute to pulmonary vascular stress and hemorrhagic risk. In cases of hsPDA, surgical ligation is often preferred over pharmacologic closure with indomethacin due to concerns regarding potential exacerbation of bleeding risk. Early echocardiographic evaluation is particularly important in extremely preterm infants, with recommendations supporting assessment within the first 12 hours of life for neonates born before 32 weeks of gestation. This early imaging allows detection of left ventricular diastolic dysfunction, which has been associated with increased risk of pulmonary hemorrhage and overall respiratory morbidity. [5] Accurate and timely integration of radiological, laboratory, and echocardiographic findings is essential for establishing diagnosis, guiding therapeutic decisions, and improving survival outcomes in affected neonates.

Treatment / Management

Neonatal pulmonary hemorrhage represents a critical emergency in neonatal intensive care medicine, and despite the absence of a definitive curative therapy, survival depends on rapid stabilization, meticulous supportive care, and coordinated interprofessional management. The central therapeutic objective is to prevent ongoing blood loss while simultaneously maintaining adequate oxygenation and ventilation. [1] Management requires a structured approach that integrates respiratory support, cardiovascular stabilization, correction of hematological abnormalities, and optimization of nutritional and metabolic needs within an intensive care environment. Initial management follows standard resuscitation principles focusing on airway, breathing, and circulation. Immediate attention is required to secure the airway and ensure effective ventilation, as respiratory compromise is often rapid and severe. Crystalloids, colloids, blood products, and vasoactive medications are administered based on hemodynamic status to restore circulating volume and maintain perfusion. [4] Endotracheal suctioning is performed cautiously to remove blood and prevent airway obstruction; however, excessive or aggressive suctioning should be avoided as it may exacerbate mucosal injury and worsen bleeding. Fraction of inspired oxygen is carefully titrated according to oxygen saturation targets to avoid both hypoxia and oxygen toxicity. [4]

Ventilatory support is a cornerstone of management. Positive end-expiratory pressure is typically maintained between 6 and 8 cm H_2O to promote alveolar stability, reduce atelectasis, and provide a tamponade effect on pulmonary capillaries, thereby limiting further hemorrhage. High-frequency oscillatory ventilation is often preferred over conventional mechanical ventilation due to its ability to improve oxygenation index and maintain consistent mean airway pressure with reduced risk of volutrauma. [1] In neonates with refractory hypoxemia or persistent respiratory acidosis despite conventional ventilation, transition to high-frequency oscillatory ventilation has been associated with rapid improvement, with reductions in oxygenation index observed within the first hour of initiation. [13] Surfactant therapy, despite its potential association with pulmonary hemorrhage in certain contexts, remains an important therapeutic intervention in affected neonates. [10] Its use in established pulmonary hemorrhage has been shown to improve lung compliance, enhance oxygenation, and reduce mortality without increasing recurrence or long-term complications. Clinical evidence from randomized trials supports its beneficial role as an adjunct therapy, particularly in preterm infants with respiratory distress. [14] Exogenous surfactants such as poractant alfa and beractant function by replacing inactivated endogenous surfactant that has been disrupted by hemorrhagic alveolar fluid. [1][10] The inactivation of native surfactant is mediated by components of hemorrhagic edema, including hemoglobin, plasma proteins, and lipid fragments of cell membranes, all of which impair surface tension regulation and worsen respiratory mechanics. [10][12][15] A favorable physiological response, reflected by a ventilatory index below 0.047, may be observed within one hour of administration. [1][10]

Adjunctive ventilatory strategies such as intermittent positive pressure ventilation can improve oxygenation by reducing alveolar-arterial gradients and correcting metabolic acidosis. [1] Increasing positive end-expiratory pressure also contributes to elevated mean airway pressure and improved alveolar recruitment. In selected cases,

pharmacological interventions such as endotracheal epinephrine have been used due to its vasoconstrictive properties, which may help reduce bleeding and decrease the need for repeated suctioning. [1] Management of coagulopathy is essential and requires prompt correction of underlying hematological abnormalities. Therapeutic options include vitamin K administration, transfusion of blood products, recombinant activated factor VII, and endotracheal haemocoagulase in selected cases. [1][16][17] Hemostatic targets are often maintained with hemoglobin levels above 12 g/dL and platelet counts exceeding 50,000/μL in the presence of active bleeding to ensure adequate oxygen delivery and clot stability. [1] Activated factor VII may be considered in life-threatening cases due to its ability to enhance thrombin generation and accelerate fibrin clot formation, thereby supporting hemostasis. [4] Additional supportive therapies have been explored in severe or refractory cases. Tolazoline, a nonselective alpha-adrenergic antagonist, may be used for its vasodilatory effects on the pulmonary circulation, while extracorporeal membrane oxygenation can serve as a rescue modality in cases of severe respiratory failure unresponsive to conventional treatment. [3][4] These interventions are typically reserved for the most critical cases due to their complexity and resource requirements. Long-term stabilization also requires attention to nutritional and metabolic support. Early placement of a peripherally inserted central catheter is recommended to facilitate delivery of total parenteral nutrition, allowing adequate provision of calories, protein, and medications, including vasopressors when necessary. Enteral feeding is introduced only after clinical stabilization to minimize the risk of further respiratory compromise. Preventive strategies are equally important in reducing incidence and severity. Selective use of exogenous surfactant rather than prophylactic administration is recommended in preterm infants, particularly those showing clinical signs of respiratory distress syndrome. [6][18] Management of hemodynamically significant patent ductus arteriosus through pharmacological agents such as indomethacin or procedural closure is essential in reducing pulmonary overcirculation and hemorrhagic risk, especially in extremely preterm neonates with restrictive interatrial communication. [5][6] Additionally, antenatal corticosteroid therapy remains one of the most effective preventive interventions, significantly reducing the risk of massive pulmonary hemorrhage and associated mortality by promoting fetal lung maturation and improving postnatal respiratory adaptation. [6] Overall, successful management depends on early recognition, rapid escalation of respiratory and cardiovascular support, correction of hematological disturbances, and careful integration of preventive strategies to reduce recurrence and improve neonatal survival outcomes.

Differential Diagnosis

The differential diagnosis of neonatal pulmonary hemorrhage encompasses a wide spectrum of disorders involving the respiratory system, cardiovascular abnormalities, infectious etiologies, structural lesions, and hematological conditions that can produce similar clinical and radiological manifestations. Accurate differentiation is essential, as many of these conditions present with respiratory distress, blood-stained airway secretions, and acute deterioration, which may closely mimic the presentation of pulmonary hemorrhage in the newborn period. One important category includes mechanical and traumatic causes such as foreign body aspiration and birth-related or iatrogenic trauma. These conditions can result in airway bleeding due to direct mucosal injury or obstruction, leading to localized or diffuse respiratory compromise. In neonates receiving respiratory support, airway trauma from instrumentation or suctioning may also contribute to blood-tinged secretions, requiring careful distinction from true pulmonary hemorrhage. Infectious causes represent another major group in the differential diagnosis. Bacterial, viral, fungal, and parasitic infections can all produce pulmonary inflammation with capillary damage, resulting in hemoptysis or bloody secretions. Severe neonatal pneumonia or sepsis may particularly resemble pulmonary hemorrhage due to diffuse alveolar involvement and systemic instability. In such cases, laboratory markers of infection and microbiological cultures are critical for differentiation.

Structural and genetic conditions such as cystic fibrosis may also present with recurrent respiratory symptoms and blood-stained secretions, although this is less common in the immediate neonatal period. Similarly, pulmonary neoplasms, though rare in neonates, can cause airway obstruction and bleeding due to tumor vascularity and tissue invasion. Pulmonary hemosiderosis is another important consideration, characterized by recurrent alveolar bleeding and accumulation of hemosiderin-laden macrophages within the lungs. Although typically a chronic condition, it can occasionally present with acute respiratory distress and mimic neonatal pulmonary hemorrhage. Cardiovascular abnormalities, particularly congenital heart lesions, are also essential in the differential diagnosis. Structural defects that result in pulmonary overcirculation or increased pulmonary venous pressure may lead to alveolar flooding with blood or blood-tinged fluid, closely resembling primary pulmonary hemorrhage. [2] These conditions often require echocardiographic evaluation for accurate identification. Additional considerations include coagulation disorders and systemic hematological abnormalities that predispose to bleeding, which may manifest with pulmonary involvement as part of a broader hemorrhagic tendency. Differentiating these conditions requires integrated clinical assessment supported by imaging, laboratory testing, and cardiac evaluation to ensure accurate diagnosis and appropriate management.

Prognosis

Neonatal pulmonary hemorrhage carries a high mortality rate, particularly among extremely premature infants who represent the most vulnerable population. Reported mortality ranges from 50% to 68%, with the majority of deaths occurring within the first seven days of life due to rapid respiratory failure and hemodynamic collapse. [1][3][9] The severity of the condition reflects both the immaturity of the pulmonary vasculature and the limited physiological

reserve of preterm neonates, which reduces their ability to compensate for acute alveolar flooding and oxygenation failure. Survivors often face significant long-term morbidity, including chronic respiratory and neurodevelopmental complications. Bronchopulmonary dysplasia is among the most common sequelae, resulting from ongoing lung injury, inflammation, and impaired alveolar development following the hemorrhagic event. Neurological impairment is also frequently reported in survivors, with outcomes including cerebral palsy, cognitive developmental delay, seizure disorders, and periventricular leukomalacia. These complications are strongly associated with periods of hypoxia, systemic instability, and prolonged intensive care support during the acute phase of illness. Despite these risks, improvements in neonatal intensive care practices, including advanced ventilation strategies, early detection methods, and better hemodynamic monitoring, have contributed to a gradual decline in mortality over recent years. [11] The role of early identification and management of hemodynamically significant patent ductus arteriosus is particularly important in modifying disease risk. Early intervention in PDA has been shown to reduce the incidence of pulmonary hemorrhage in very preterm neonates by limiting pulmonary overcirculation and reducing capillary stress. However, evidence suggests that while such interventions may reduce the occurrence of pulmonary hemorrhage, they do not necessarily translate into significant improvements in overall survival rates. [7][9] This indicates that pulmonary hemorrhage is influenced by multiple interacting factors beyond ductal patency alone, including prematurity-related vulnerability and systemic instability.

Complications

Neonates who experience pulmonary hemorrhage are at increased risk of a range of acute and long-term complications involving the respiratory, neurological, and cardiovascular systems. Acute complications frequently include respiratory distress syndrome, pneumothorax, circulatory shock, and severe intraventricular hemorrhage. [9] These conditions often occur concurrently due to the fragile physiological state of preterm infants and the shared underlying mechanisms of vascular instability and hypoxia. The accumulation of blood within the alveolar spaces, combined with inflammatory mediators released during hemorrhage, contributes to significant lung injury and structural remodeling. One of the most important long-term complications is bronchopulmonary dysplasia, also known as chronic lung disease of prematurity. This condition develops as a result of ongoing inflammation, fibrosis, and disrupted alveolar development following acute pulmonary injury. [7][11] Radiological findings often include diffuse haziness and fine interstitial markings, reflecting chronic structural changes within the lung parenchyma. The need for prolonged mechanical ventilation further exacerbates lung injury by promoting barotrauma and volutrauma. Extended oxygen therapy, while essential for survival, may contribute to secondary lung damage through the generation of reactive oxygen species and increased inflammatory cytokine expression. [7] This oxidative stress further impairs alveolar development and increases susceptibility to chronic respiratory morbidity. Additional complications include long-term neurological sequelae such as cerebral palsy, cognitive impairment, seizure disorders, and periventricular leukomalacia, which are often related to hypoxic-ischemic injury and prolonged systemic instability during the acute phase. [6] Prolonged hospitalization is common in affected neonates, reflecting both the severity of the initial insult and the need for extended respiratory and nutritional support. These complications highlight the systemic impact of pulmonary hemorrhage and emphasize the importance of early stabilization, careful ventilatory management, and strategies aimed at minimizing secondary injury.

Patient Education

Prevention and caregiver education play a central role in reducing both the incidence and severity of neonatal pulmonary hemorrhage, particularly among high-risk preterm populations. Preventive strategies begin during the antenatal period, where the administration of corticosteroids to mothers at risk of preterm delivery significantly improves fetal lung maturation and reduces the likelihood of severe respiratory complications after birth. Careful prenatal planning and timely referral to specialized neonatal centers are also essential to ensure that high-risk deliveries occur in environments equipped with advanced respiratory and intensive care support. Postnatal preventive measures include judicious use of surfactant therapy, avoiding unnecessary prophylactic administration, and ensuring its use is guided by clear clinical indications such as established respiratory distress syndrome. Careful monitoring and early management of patent ductus arteriosus are also important in reducing pulmonary overcirculation and minimizing hemorrhagic risk. These strategies collectively aim to reduce physiological stress on the immature lung and prevent progression to severe hemorrhage. Parental education is equally important in improving outcomes. Families should be informed about risk factors such as prematurity, low birth weight, and the need for intensive respiratory support. Clear communication regarding potential complications, treatment approaches, and long-term outcomes helps parents participate in informed decision-making and understand the importance of early intervention and specialized neonatal care. Education also reinforces the value of prenatal care, early hospital presentation, and adherence to recommended obstetric and neonatal follow-up plans.

Enhancing Healthcare Team Outcomes

The management of neonatal pulmonary hemorrhage requires a coordinated interprofessional approach involving neonatologists, pediatricians, respiratory therapists, nurses, and pharmacists. Each discipline contributes essential expertise to ensure rapid diagnosis, effective stabilization, and ongoing supportive care. Physicians and advanced neonatal practitioners are responsible for clinical decision-making, including ventilatory strategies, surfactant

administration, and hemodynamic stabilization. Respiratory therapists play a critical role in optimizing ventilator settings to maintain oxygenation while minimizing ventilator-induced lung injury. Bedside nurses are essential for continuous monitoring of vital signs, oxygenation status, and early detection of clinical deterioration. Their close patient contact allows for immediate recognition of changes in respiratory or cardiovascular status, enabling timely escalation of care. Pharmacists contribute by ensuring safe and accurate administration of blood products, vasoactive agents, and coagulation factors, all of which are essential in stabilizing circulation and controlling hemorrhage. Effective communication among team members is a key determinant of successful outcomes. Structured handovers, multidisciplinary rounds, and real-time collaboration ensure continuity of care and reduce the risk of delayed interventions. Regular training sessions and simulation-based emergency drills improve team preparedness and enhance coordination during acute hemorrhagic events. This collaborative framework promotes patient safety, improves survival rates, and reduces the burden of complications associated with pulmonary hemorrhage in newborns.

Conclusion

Neonatal pulmonary hemorrhage represents a rapidly progressive and life-threatening condition that primarily affects premature and low birth weight infants. The disorder reflects a complex interaction between pulmonary immaturity, cardiovascular transition failure, and external medical interventions within neonatal intensive care settings. Early recognition remains the most critical determinant of outcome, as clinical deterioration can occur within hours and frequently leads to severe respiratory failure and hemodynamic collapse. The evidence presented demonstrates that pulmonary hemorrhage is not a single-etiology disease but a multifactorial process involving surfactant dysfunction, patent ductus arteriosus, ventilatory injury, and systemic instability. Effective management depends on immediate stabilization using structured resuscitation protocols, optimized ventilatory support, and timely correction of hematological and circulatory disturbances. High-frequency oscillatory ventilation, controlled oxygen delivery, and judicious use of surfactant therapy remain key therapeutic strategies that improve oxygenation and reduce mortality risk. In parallel, correction of coagulopathy and maintenance of adequate hemoglobin and platelet levels are essential to control ongoing bleeding and support tissue oxygen delivery. The role of interprofessional collaboration is central, as coordinated actions between physicians, nurses, respiratory therapists, and pharmacists directly influence survival and recovery outcomes. Preventive strategies, including antenatal corticosteroids, careful management of patent ductus arteriosus, and selective surfactant administration, significantly reduce incidence in high-risk populations. However, despite advances in neonatal care, mortality remains high, particularly among extremely preterm infants, and long-term complications such as bronchopulmonary dysplasia and neurodevelopmental impairment remain common in survivors. Overall, pulmonary hemorrhage in newborns remains a critical neonatal emergency requiring high clinical vigilance, rapid intervention, and integrated multidisciplinary care. Continued improvement in early detection, standardized management protocols, and neonatal intensive care practices is essential to reduce mortality and improve long-term outcomes in this vulnerable population.

References

1. Barnes ME, Feeney E, Duncan A, Jassim S, MacNamara H, O'Hara J, Refila B, Allen J, McCollum D, Meehan J, Mullaly R, O'Cathain N, Roche E, Molloy EJ. Pulmonary haemorrhage in neonates: Systematic review of management. Acta Paediatr. 2022 Feb;111(2):236-244.
2. Del Duca F, Maiese A, Spina F, Visi G, La Russa R, Santoro P, Pignotti MS, Frati P, Fineschi V. Idiopathic Pulmonary Hemorrhage in Infancy: A Case Report and Literature Review. Diagnostics (Basel). 2023 Mar 28;13(7)
3. Gezmu AM, Tefera E, Mochankana K, Imran F, Joel D, Pelaelo I, Nakstad B. Pulmonary hemorrhage and associated risk factors among newborns admitted to a tertiary level neonatal unit in Botswana. Front Pediatr. 2023;11:1171223.
4. Hadžić D, Zulić E, Salkanović-Delibegović S, Softić D, Kovačević D, Softić D. SHORT-TERM OUTCOME OF MASSIVE PULMONARY HEMORRHAGE IN PRETERM INFANTS IN TUZLA CANTON. Acta Clin Croat. 2021 Mar;60(1):82-88.
5. Kappico JM, Cayabyab R, Ebrahimi M, Uzunyan MY, Barton L, Siassi B, Ramanathan R. Pulmonary hemorrhage in extremely low birth weight infants: Significance of the size of left to right shunting through a valve incompetent patent foramen ovale. J Perinatol. 2022 Sep;42(9):1233-1237.
6. Jung JK, Kim EY, Heo JS, Park KH, Choi BM. Analysis of perinatal risk factors for massive pulmonary hemorrhage in very low birth weight infant: A nationwide large cohort database. Early Hum Dev. 2024 Apr;191:105977.
7. Bozkaya A, Yurttutan S, Özkars MY, Doğaner A. Respiratory problems in preterm infants with pulmonary hemorrhage. J Matern Fetal Neonatal Med. 2022 Dec;35(25):7505-7510.
8. Cardona VQ, Joshi S, Conway D, Menkiti OR. Severe Pulmonary Hemorrhage in a Neonate With Hypoxic Ischemic Encephalopathy and Sepsis Managed on Extracorporeal Membrane Oxygenation. ASAIO J. 2022 Jun 01;68(6):e106-e109.
9. Ahmad KA, Bennett MM, Ahmad SF, Clark RH, Tolia VN. Morbidity and mortality with early pulmonary haemorrhage in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 2019 Jan;104(1):F63-F68.
10. Aziz A, Ohlsson A. Surfactant for pulmonary haemorrhage in neonates. Cochrane Database Syst Rev. 2020 Feb 03;2(2):CD005254.

11. Lee M, Wu K, Yu A, Roumiantsev S, Shailam R, Nimkin K, Sagar P. Pulmonary hemorrhage in neonatal respiratory distress syndrome: Radiographic evolution, course, complications and long-term clinical outcomes. J Neonatal Perinatal Med. 2019;12(2):161-171.
12. Dargaville PA, Herting E, Soll RF. Neonatal surfactant therapy beyond respiratory distress syndrome. Semin Fetal Neonatal Med. 2023 Dec;28(6):101501.
13. Ko SY, Chang YS, Park WS. Massive pulmonary hemorrhage in newborn infants successfully treated with high frequency oscillatory ventilation. J Korean Med Sci. 1998 Oct;13(5):495-9.
14. Bozdağ Ş, Dilli D, Gökmen T, Dilmen U. Comparison of two natural surfactants for pulmonary hemorrhage in very low-birth-weight infants: a randomized controlled trial. Am J Perinatol. 2015 Feb;32(3):211-8.
15. Desai RK, Yildiz Atar H, Lakshminrusimha S, Ryan RM. Use of surfactant beyond respiratory distress syndrome, what is the evidence? J Perinatol. 2024 Apr;44(4):478-487.
16. Grizelj R, Vuković J, Filipović-Grcić B, Sarić D, Luetić T. Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage. Blood Coagul Fibrinolysis. 2006 Jul;17(5):413-5.
17. Shi Y, Tang S, Li H, Zhao J, Pan F. New treatment of neonatal pulmonary hemorrhage with hemocoagulase in addition to mechanical ventilation. Biol Neonate. 2005;88(2):118-21.
18. Sweet DG, Carnielli VP, Greisen G, Hallman M, Klebermass-Schrehof K, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology. 2023;120(1):3-23.